Roni Ben-Ami

Roni Ben-Ami

Auto-generated profile, based on publicly available information

Roni Ben-Ami

The Hebrew University of Jerusalem

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2021 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
NBNetta Barak
Netta Barak
RBRoni Ben-Ami
Roni Ben-Ami
TSTal Sido
Tal Sido
APAmir Perri
Amir Perri
ASAviad Shtoyer
Aviad Shtoyer
MYMoran Yassour
Moran Yassour
Adaptive sample pooling for SARS-CoV-2 testing based on positivity rates spares 76% of test reactions without compromising specificity or sensitivity.

20 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJoshua Moss
Joshua Moss
RBRoni Ben-Ami
Roni Ben-Ami
ESEla Shai
Ela Shai
OGOfer Gal-Rosenberg
Ofer Gal-Rosenberg
YKYosef Kalish
Yosef Kalish
YDYuval Dor
Yuval Dor
Circulating cell-free DNA (cfDNA) fragments are a biological analyte with extensive utility in diagnostic medicine. Understanding the source of cfDNA and mechanisms of release is crucial for designing and interpreting cfDNA-based liquid biopsy assays. Using cell type-specific methylation markers as well as genome-wide methylation analysis, we determine that megakaryocytes, the precursors of anuclear platelets, are major contributors to cfDNA (~26%), while erythroblasts contribute 1–4% of cfDNA in healthy individuals. Surprisingly, we discover that platelets contain genomic DNA fragments originating in megakaryocytes, contrary to the general understanding that platelets lack genomic DNA. Megakaryocyte-derived cfDNA is increased in pathologies involving increased platelet production (Essential Thrombocythemia, Idiopathic Thrombocytopenic Purpura) and decreased upon reduced platelet production due to chemotherapy-induced bone marrow suppression. Similarly, erythroblast cfDNA is reflective of erythrocyte production and is elevated in patients with thalassemia. Megakaryocyte- and erythroblast-specific DNA methylation patterns can thus serve as biomarkers for pathologies involving increased or decreased thrombopoiesis and erythropoiesis, which can aid in determining the etiology of aberrant levels of erythrocytes and platelets.

13 December 2023 in Gut
Verified
Journal Article
Open access
PDF file
RBRoni Ben-Ami
Roni Ben-Ami
QWQiao-Li Wang
Qiao-Li Wang
JZJinming Zhang
Jinming Zhang
JSJulianna G Supplee
Julianna G Supplee
JFJohannes F Fahrmann
Johannes F Fahrmann
BWBrian M Wolpin
Brian M Wolpin
Objective Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at an advanced stage. Liquid biopsy approaches may facilitate detection of early stage PDAC when curative treatments can be employed. Design To assess circulating marker discrimination in training, testing and validation patient cohorts (total n=426 patients), plasma markers were measured among PDAC cases and patients with chronic pancreatitis, colorectal cancer (CRC), and healthy controls. Using CA19-9 as an anchor marker, measurements were made of two protein markers (TIMP1, LRG1) and cell-free DNA (cfDNA) pancreas-specific methylation at 9 loci encompassing 61 CpG sites. Results Comparative methylome analysis identified nine loci that were differentially methylated in exocrine pancreas DNA. In the training set (n=124 patients), cfDNA methylation markers distinguished PDAC from healthy and CRC controls. In the testing set of 86 early stage PDAC and 86 matched healthy controls, CA19-9 had an area under the receiver operating characteristic curve (AUC) of 0.88 (95% CI 0.83 to 0.94), which was increased by adding TIMP1 (AUC 0.92; 95% CI 0.88 to 0.96; p=0.06), LRG1 (AUC 0.92; 95% CI 0.88 to 0.96; p=0.02) or exocrine pancreas-specific cfDNA methylation markers at nine loci (AUC 0.92; 95% CI 0.88 to 0.96; p=0.02). In the validation set of 40 early stage PDAC and 40 matched healthy controls, a combined panel including CA19-9, TIMP1 and a 9-loci cfDNA methylation panel had greater discrimination (AUC 0.86, 95% CI 0.77 to 0.95) than CA19-9 alone (AUC 0.82; 95% CI 0.72 to 0.92). Conclusion A combined panel of circulating markers including proteins and methylated cfDNA increased discrimination compared with CA19-9 alone for early stage PDAC.

21 April 2022 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
JMJudith Magenheim
Judith Magenheim
ARAriel Rokach
Ariel Rokach
APAyelet Peretz
Ayelet Peretz
NLNetanel Loyfer
Netanel Loyfer
GCGordon Cann
Gordon Cann
YDYuval Dor
Yuval Dor
Doses of 3H-acetaminophen (300-750 mg/kg) that cause necrosis in mice were shown to result in large amounts of radiolabeled material covalently bound to mouse liver protein in vivo (2 nmol/mg of protein or approximately one molecule bound per two molecules of protein in microsomes and cytoplasm). Both covalent binding and hepatic necrosis were dose dependent, and the peak level of binding preceded the development of recognizable necrosis by at least one to two hours. Pretreatment of mice with phenobarbital, piperonyl butoxide or cobaltous chloride, which changed the rate of metabolism of 3H-acetaminophen and altered the severity of hepatic necrosis, similarly affected the extent of hepatic binding of radiolabeled metabolite. Furthermore, the degree of binding in individual mice was always directly proportional to the severity of hepatic necrosis regardless of the biologic variation among various animals. Accordingly, we propose that acetaminophen-induced hepatic necrosis may be caused by the covalent binding of a chemically reactive metabolite to vital hepatsic macromolecules.

20 October 2020 in medRxiv
Verified
Preprint
Open access
PDF file
NBNetta Barak
Netta Barak
RBRoni Ben-Ami
Roni Ben-Ami
TSTal Sido
Tal Sido
APAmir Perri
Amir Perri
ASAviad Shtoyer
Aviad Shtoyer
MYMoran Yassour
Moran Yassour
Pooling multiple swab samples prior to RNA extraction and RT-PCR analysis was proposed as a strategy to reduce costs and increase throughput of SARS-CoV-2 tests. However, reports on practical large-scale group testing for SARS-CoV-2 have been scant. Key open questions concern reduced sensitivity due to sample dilution; the rate of false positives; the actual efficiency (number of tests saved by pooling) and the impact of infection rate in the population on assay performance. Here we report analysis of 133,816 samples collected at April-September 2020, tested by pooling for the presence of SARS-CoV-2. We spared 76% of RNA extraction and RT-PCR tests, despite the reality of frequently changing prevalence rate (0.5%-6%). Surprisingly, we observed pooling efficiency and sensitivity that exceed theoretical predictions, which resulted from non-random distribution of positive samples in pools. Overall, the findings strongly support the use of pooling for efficient large high throughput SARS-CoV-2 testing.

22 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RBRoni Ben-Ami
Roni Ben-Ami
AKAgnes Klochendler
Agnes Klochendler
MSMatan Seidel
Matan Seidel
TSTal Sido
Tal Sido
OGOri Gurel-Gurevich
Ori Gurel-Gurevich
Yotam DrierYotam Drier
Yotam Drier
Testing for active SARS-CoV-2 infection is a fundamental tool in the public health measures taken to control the COVID-19 pandemic. Due to the overwhelming use of SARS-CoV-2 RT-PCR tests worldwide, availability of test kits has become a major bottleneck. Here we demonstrate pooling strategies to perform RNA extraction and RT-PCR in pools, significantly increasing throughput while maintaining clinical sensitivity. We implemented the method in a routine clinical diagnosis setting of asymptomatic populations, and already tested 5,464 individuals for SARS-CoV-2 using 731 RNA extraction and RT-PCR kits. We identified six SARS-CoV-2 positive patients corresponding to 0.11% of the tested population.